10-QPeriod: Q1 FY2025

Cigna Group Quarterly Report for Q1 Ended Mar 31, 2025

Filed May 2, 2025For Securities:CI

Summary

Cigna Group (CI) reported a significant turnaround in its financial performance for the first quarter of 2025, moving from a net loss of $277 million in Q1 2024 to a net income of $1.323 billion, resulting in a diluted EPS of $4.85 compared to ($0.97) in the prior year. This improvement was largely driven by the absence of substantial net investment losses experienced in Q1 2024, which were primarily related to equity security impairments. Total revenues saw a robust 14% increase year-over-year, reaching $65.5 billion, fueled by growth across all segments, particularly a 16% rise in Pharmacy revenues. The company also successfully completed the divestiture of its Medicare Advantage and related businesses to HCSC for an increased purchase price, which is expected to provide additional proceeds in Q4 2025. While operating expenses rose 16%, the strong revenue growth and the elimination of prior-year investment losses contributed to the substantial net income improvement. Cigna also announced a new $6.5 billion credit facility in April 2025, underscoring its strong liquidity position.

Financial Highlights

47 data points
Beta

Revenue

$65.50B

26.1% Gross Margin

Net Income

$1.32B

2.0% Net Margin

EPS (Diluted)

$4.85

Total Assets

$150.66B

Cash & Equivalents

$8.38B

Free Cash Flow

$1.92B

Financial Statements
Beta
Revenue$65.50B
Cost of Revenue$48.40B
Gross Profit$17.10B
SG&A Expenses$4.21B
Operating Income$1.97B
Interest Expense$362.00M
Net Income$1.32B
EPS (Basic)$4.88
EPS (Diluted)$4.85
Shares Outstanding (Diluted)272.95M

Key Highlights

  • 1Reported a substantial swing from a net loss of $277 million in Q1 2024 to a net income of $1.323 billion in Q1 2025, with diluted EPS at $4.85 compared to ($0.97).
  • 2Total revenues increased by 14% to $65.5 billion, driven by strong performance in Pharmacy revenues (up 16%) and Premiums (up 10%).
  • 3Completed the divestiture of its Medicare Advantage and related businesses to HCSC on March 19, 2025, receiving $4.2 billion in cash proceeds at closing and expecting an additional $0.6 billion later in the year.
  • 4Adjusted income from operations slightly decreased by 2% to $1.84 billion, primarily due to the absence of state tax benefits from the prior year and lower earnings in the Cigna Healthcare segment, partially offset by growth in Evernorth Health Services.
  • 5Pharmacy and other service costs increased by 17%, and medical costs increased by 11%, reflecting higher utilization and costs, but were managed effectively against revenue growth.
  • 6Selling, general, and administrative (SG&A) expenses increased by 14%, largely due to costs associated with the Strategic Optimization Program and the HCSC transaction.
  • 7The company announced a new $6.5 billion, five-year revolving credit facility in April 2025, enhancing its liquidity and financial flexibility.

Frequently Asked Questions

The primary driver for the substantial increase in net income was the absence of significant net investment losses recorded in Q1 2024, which were mainly due to the impairment of equity securities. In Q1 2025, net investment losses were negligible at $2 million, compared to $1.836 billion in the prior year's comparable quarter.

The divestiture of the Medicare Advantage and related businesses to HCSC, completed on March 19, 2025, resulted in a gain on sale of businesses of $41 million recognized in the current quarter. The transaction also led to a decrease in medical customers and a reduction in unpaid claims and claim expenses, reflecting the sale of these operations. The company received $4.2 billion in cash proceeds at closing, with an additional $0.6 billion expected later in 2025.

Cigna Group maintains strong liquidity, highlighted by its $6.5 billion revolving credit facility established in April 2025 and $8.5 billion in cash and short-term investments as of March 31, 2025. The company's capital deployment strategy prioritizes investing in capital expenditures, maintaining financial strength ratings, repaying debt, paying dividends, considering strategic acquisitions, and returning capital to shareholders through share repurchases. Share repurchases totaled $1.5 billion in Q1 2025.

The company commenced an enterprise-wide 'Strategic Optimization Program' in 2025 expected to continue through December 2026. This program incurred $215 million in pre-tax costs during Q1 2025, primarily for employee severance, which impacted Selling, General, and Administrative (SG&A) expenses. These costs are part of the company's ongoing efforts to improve efficiency and enhance customer experiences.